Jagsonpal Pharmaceuticals Limited announced the launch of QueeZy-ER® providing relief from Nausea and Vomiting in P pregnancy (NVP). The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation. The product comes with a tablet-in-tablet technology, which allows dispersal of uniform dosage at two different time-periods from the same dose, thereby allowing for 24-hour benefit to the patient.

This allows for a single dose as against the conventional requirement of up to 3-4 tablets a day. Further, the overall therapy cost per day is lower as compared to conventional pills. The combination of Doxylamine succinating 20mg and Pyridoxine hydro chloride 20mg is the only USFDA approved combination for NVP treatment.

Key benefits of Queezy-ER®?. Extended-Release: Unique dual-release formulation for immediate and prolonged relief, reducing the need for frequent dosing. Improved adherence: Minimizes the necessity for frequent dosing, enhancing patient compliance for a more consistent approach to symptom management.

Safety Assurance: Formulated with ingredients known for their safety profile in pregnant women, ensuring a secure and reliable option for managing symptoms.